$CCRN

Bhamidipati Venkat sold (to issuer) $394K of CCRN

Bhamidipati Venkat sold (to issuer) 29,759 shares of CROSS COUNTRY HEALTHCARE INC (CCRN) at $13.25 ($0.39M total) on 2026-07-21.

Original reporting
SEC EDGAR · Bhamidipati Venkat
Published Jul 21, 2026, 8:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 21, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CCRN
Neutral
medium confidence
Mentioned
$CCRN
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CCRNNeutralLow
01

Why it matters

The newest fact is the director’s sale of 29,759 shares at $13.25 on 2026-07-21, totaling about $394.3K, with holdings reduced to 0 shares.

02

Market read

Traders may note the insider sale, but there is no accompanying fundamental or regulatory news to drive a durable repricing.

03

What to watch

Insider sales can be driven by liquidity needs, diversification, or mechanical buyback participation; the filing provides no rationale or linkage to company performance.

Relevance 4/10Novelty 2/10Timing: Filed 2026-07-21, after-hours SEC Form 4 disclosure

Background

The article is an SEC Form 4 insider transaction disclosure for Cross Country Healthcare (CCRN).

Company-level read

Ticker impact

$CCRNNeutralMedium confidence
Context

Form 4 shows director Bhamidipati Venkat sold 29,759 shares of Cross Country Healthcare at $13.25 on 2026-07-21, leaving 0 shares.

Expected impact

Low likelihood of a sustained price move based solely on this Form 4; any reaction would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a disclosed insider transaction, but it does not include new operating results, guidance, or regulatory/legal developments. Sale-to-issuer codes often relate to structured programs, reducing interpretive value.

Market effects

Minimal. This is company-specific insider transaction data with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

If the sale-to-issuer code reflects a non-routine buyback participation, the absence of a 10b5-1 plan could be interpreted as less programmatic and therefore slightly more informative.

Key entities

  • CROSS COUNTRY HEALTHCARE INC

    Company whose director insider transaction is disclosed on Form 4.

  • Bhamidipati Venkat

    Director who sold shares to the issuer on 2026-07-21.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LWAYLow

Divisadero Street Capital Management, LP (Zolezzi William) purchased $6.1M of LWAY (indirect holdings)

Divisadero Street Capital Management, LP purchased 246,568 indirectly-held shares of Lifeway Foods, Inc. (LWAY) at an average of $24.85 ($24.69–$24.87, $6.13M total) across 3 trades over 2026-08-13 to 2026-08-17. Filed jointly with Divisadero Street Partners GP, LLC (10% owner), Divisadero Street Capital, LLC (10% owner), Divisadero Street Partners, L.P. (10% owner) and Zolezzi William (10% owner).